SCHEMBL6073628

SCHEMBL6073628

N#Cc1cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2nc1NC(=O)NC1CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.51
CDK4 P11802 16/20 0.47
CCND1 P24385 15/20 0.47
CDK2 P24941 13/20 0.47
CCNA2 P20248 12/20 0.47
FGFR1 P11362 11/20 0.47
FGFR2 P21802 10/20 0.47
FGFR4 P22455 10/20 0.47
FGFR3 P22607 10/20 0.47
CCNE1 P24864 3/20 0.47
CDK1 P06493 3/20 0.47
CCNB1 P14635 3/20 0.47
CCND2 P30279 3/20 0.46
CCND3 P30281 3/20 0.46
CCNA1 P78396 3/20 0.46
CCNE2 O96020 1/20 0.46
CDK6 Q00534 2/20 0.46
NUAK1 O60285 2/20 0.46
CCNT1 O60563 2/20 0.46
CDK7 P50613 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073818 0.89 CDK4 (0.55) SYKCDK4CCND1CDK2CCNA2
SCHEMBL6074793 0.88 SYK (0.53) SYKCDK4CCND1CDK2CCNA2
SCHEMBL6073707 0.88 CDK4 (0.55) SYKCDK4CCND1CDK2CCNA2
SCHEMBL6073499 0.88 CDK4 (0.55) SYKCDK4CCND1CDK2CCNA2
SCHEMBL6074226 0.83 CDK4 (0.54) SYKCDK4CCND1CDK2CCNA2
SCHEMBL6073405 0.82 CDK4 (0.54) SYKCDK4CCND1CDK2CCNA2
SCHEMBL6074210 0.80 CDK4 (0.58) SYKCDK4CCND1CDK2CCNA2
SCHEMBL6073443 0.80 CDK4 (0.57) SYKCDK4CCND1CDK2CCNA2
SCHEMBL6073865 0.80 CDK4 (0.57) SYKCDK4CCND1CDK2CCNA2
SCHEMBL6073534 0.79 CDK4 (0.56) SYKCDK4CCND1CDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US claimed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 SYK 1176/4885CDK4 19/4885CCND1 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.